RADICAVA ORS® (edaravone) is an ORAL administration option of RADICAVA® (edaravone), an ALS treatment shown to slow the loss of physical function.
FDA-APPROVED & AVAILABLE
For Your Moments Big and Small
A patient-focused approach for ALS and treatment support
No matter where you are in your ALS journey—from diagnosis to treatment—the JourneyMate Support Program™ gives you the understanding, answers, and resources to help you move forward.
If you're new to treatment, the program can help you learn more about RADICAVA®. If you're currently using RADICAVA® IV, the program can help you learn more about switching to RADICAVA ORS®.
The RADICAVA® Educational Communications Series—Sign Up Today
Join our community of 18,000+ people who’ve signed up to learn more about RADICAVA ORS® or RADICAVA® IV and why it matters to patients and caregivers.
Help other people living with ALS by sharing your experience with ALS and RADICAVA®. See how you can share
ALS=amyotrophic lateral sclerosis; IV=intravenous.
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of July 2023. Not independently verified. Return to content
bPatients who started RADICAVA ORS® or RADICAVA® IV between June 2022 and April 2023 and continued for 3 months or more through July 2023. Return to content
cThe initial treatment cycle starts with daily dosing of RADICAVA ORS® for 14 days followed by a 14-day drug-free period. Subsequent treatment cycles include daily dosing 10 out of 14 days followed by a 14-day drug-free period. Return to content
dUse the provided 5 mL syringe that comes with the product. Do not use a household teaspoon to measure your medication. Return to content